Q1 Financial Results Strongest Since Q4 2018; Q2 Revenue Already Exceeds Q2 2020. Purchase of Accretive, Eco-Friendly Agrochemical Supplier Nearing Close.
Q1 Financial Results Strongest Since Q4 2018; Q2 Revenue Already Exceeds Q2 2020.
Purchase of Accretive, Eco-Friendly Agrochemical Supplier Nearing Close.
SOUTH EASTON, MA / ACCESSWIRE / May 18, 2021 / Pressure BioSciences, Inc.. (OTCQB:PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its First Quarter 2021 financial results and provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a Company website link).
The teleconference will include a Company presentation followed by a Question & Answer period.
Date: Wednesday, May 19, 2021. Time: 4:30 PM Eastern Time (ET).
To attend this teleconference, live by telephone: Dial-in (877)-407-8033 (North America); 201-689-8033 (International). Verbal Passcode: PBI Q1 2021 Financial Call and Business Update.
For those unable to participate in the live teleconference, a replay will be available beginning Thursday, May 20, 2021. The replay will be accessible via telephone and the Company’s website for 30 days. Replay Number: (877)-481-4010 (North America); (919) 882-2331 (Int’l); Replay Passcode: 41416.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
For more information about PBI and this press release, please click on the following link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.
Investor Contacts:
Richard T. Schumacher, President and CEO (T) (508) 230-1828
Jeffrey N. Peterson, Chairman of the Board (F) 508-230-1829
SOURCE: Pressure BioSciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/647913/With-Sales-Up-Over-120-Pressure-BioSciences-to-Host-Q1-2021-Financial-Results-and-Business-Update-on-Wednesday-May-19-2021
